Syringeable immunotherapeutic nanogel reshapes tumor microenvironment and prevents tumor metastasis and recurrence

Chanyoung Song, Hathaichanok Phuengkham, Young Seob Kim, Dinh Van Vuong, Inho Lee, Il Woo Shin, Hong Sik Shin, Seung Mo Jin, Soong Ho Um, Hyunseung Lee, Kwan Soo Hong, Seon-Mi Jin, Eunji Lee, Tae Heung Kang (), Yeong-Min Park () and Yong Taik Lim ()
Additional contact information
Chanyoung Song: Sungkyunkwan University
Hathaichanok Phuengkham: Sungkyunkwan University
Young Seob Kim: Konkuk University
Dinh Van Vuong: Sungkyunkwan University
Inho Lee: Sungkyunkwan University
Il Woo Shin: Sungkyunkwan University
Hong Sik Shin: Sungkyunkwan University
Seung Mo Jin: Sungkyunkwan University
Soong Ho Um: Sungkyunkwan University
Hyunseung Lee: Korea Basic Science Institute
Kwan Soo Hong: Korea Basic Science Institute
Seon-Mi Jin: Gwangju Institute of Science and Technology
Eunji Lee: Gwangju Institute of Science and Technology
Tae Heung Kang: Konkuk University
Yeong-Min Park: Konkuk University
Yong Taik Lim: Sungkyunkwan University

Nature Communications, 2019, vol. 10, issue 1, 1-15

Abstract: Abstract The low response rate of current cancer immunotherapy suggests the presence of few antigen-specific T cells and a high number of immunosuppressive factors in tumor microenvironment (TME). Here, we develop a syringeable immunomodulatory multidomain nanogel (iGel) that overcomes the limitation by reprogramming of the pro-tumoral TME to antitumoral immune niches. Local and extended release of immunomodulatory drugs from iGel deplete immunosuppressive cells, while inducing immunogenic cell death and increased immunogenicity. When iGel is applied as a local postsurgical treatment, both systemic antitumor immunity and a memory T cell response are generated, and the recurrence and metastasis of tumors to lungs and other organs are significantly inhibited. Reshaping of the TME using iGel also reverts non-responding groups to checkpoint blockade therapies into responding groups. The iGel is expected as an immunotherapeutic platform that can reshape immunosuppressive TMEs and synergize cancer immunotherapy with checkpoint therapies, with minimized systemic toxicity.

Date: 2019
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-019-11730-8 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-019-11730-8

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-019-11730-8

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().